TY - JOUR T1 - Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - S32 LP - S37 DO - 10.3949/ccjm.79.s2.07 VL - 79 IS - 5 e-suppl 1 AU - Gregory M.M. Videtic Y1 - 2012/05/01 UR - http://www.ccjm.org/content/79/5_e-suppl_1/S32.abstract N2 - The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation. ER -